These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 20644487)

  • 1. Orally administered manganese with and without ascorbic acid as a liver-specific contrast agent and bowel marker for magnetic resonance imaging: phase I clinical trial assessing efficacy and safety.
    Leander P; Golman K; Månsson S; Höglund P
    Invest Radiol; 2010 Sep; 45(9):559-64. PubMed ID: 20644487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Manganese-based oral contrast agent for liver magnetic resonance imaging: evaluation of the time course and dose response of liver signal intensity enhancement.
    Rief M; Huppertz A; Asbach P; Franiel T; Schwenke C; Hamm B; Taupitz M; Wagner M
    Invest Radiol; 2010 Sep; 45(9):565-71. PubMed ID: 20644484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mangafodipir trisodium (MnDPDP)-enhanced magnetic resonance imaging of the liver and pancreas.
    Wang C
    Acta Radiol Suppl; 1998; 415():1-31. PubMed ID: 9571956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orally administered manganese chloride: enhanced detection of hepatic tumors in rats.
    Kreft BP; Baba Y; Tanimoto A; Finn JP; Stark DD
    Radiology; 1993 Feb; 186(2):543-8. PubMed ID: 8421762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new manganese-based oral contrast agent (CMC-001) for liver MRI: pharmacological and pharmaceutical aspects.
    Jørgensen JT; Rief M; Brismar TB; Wagner M; Albiin N
    Acta Radiol; 2012 Sep; 53(7):707-13. PubMed ID: 22821959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ferric ammonium citrate as a positive bowel contrast agent for MR imaging of the upper abdomen. Safety and diagnostic efficacy.
    Kivelitz D; Gehl HB; Heuck A; Krahe T; Taupitz M; Lodemann KP; Hamm B
    Acta Radiol; 1999 Jul; 40(4):429-35. PubMed ID: 10394873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multisite phase III study of the safety and efficacy of a new manganese chloride-based gastrointestinal contrast agent for MRI of the abdomen and pelvis.
    Small WC; DeSimone-Macchi D; Parker JR; Sukerkar A; Hahn PF; Rubin DL; Zelch JV; Kuhlman JE; Outwater EK; Weinreb JC; Brown JJ; de Lange EE; Woodward PJ; Arildsen R; Foster GS; Runge VM; Aisen AM; Muroff LR; Thoeni RF; Parisky YR; Tanenbaum LN; Totterman S; Herfkens RJ; Knudsen J; Bernardino ME
    J Magn Reson Imaging; 1999 Jul; 10(1):15-24. PubMed ID: 10398973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast multiplanar spoiled gradient-recalled imaging of the liver: pulse sequence optimization and comparison with spin-echo MR imaging.
    Low RN; Francis IR; Herfkens RJ; Jeffrey RB; Glazer GM; Foo TK; Shimakawa A; Pelc NJ
    AJR Am J Roentgenol; 1993 Mar; 160(3):501-9. PubMed ID: 8381572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of fast and ultrafast T2-weighted MR imaging sequences in hepatic enhancement with ferumoxides: comparison with conventional spin-echo sequence.
    Abe Y; Yamashita Y; Namimoto T; Tang Y; Takahashi M
    Radiat Med; 2000; 18(2):97-105. PubMed ID: 10888042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T1 efficacy of EVP-ABD: a potential manganese-based MR contrast agent for hepatic vascular and tissue phase imaging.
    Zuo CS; Seoane P; Lanigan T; Harnish P; Prasad PV; Storey P; Li W; Rofsky NM
    J Magn Reson Imaging; 2002 Dec; 16(6):668-75. PubMed ID: 12451580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive bowel contrast agent for MR imaging of the abdomen: phase II and III clinical trials.
    Patten RM; Lo SK; Phillips JJ; Bowman SC; Glazer GM; Wall SD; Bova JG; Harris RD; Wheat RL; Johnson CD
    Radiology; 1993 Oct; 189(1):277-83. PubMed ID: 8372205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of a novel hepatobiliary MR contrast agent, Gd-DTPA-DeA: results of phase I and phase II clinical trials.
    Tanimoto A; Kadoya M; Kawamura Y; Kuwatsuru R; Gokan T; Hirohashi S
    J Magn Reson Imaging; 2006 Apr; 23(4):499-508. PubMed ID: 16534755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral manganese for liver imaging at three different field strengths.
    Thomsen HS; Loegager V; Noergaard H; Chabanova E; Moller JM; Sonne J
    Acad Radiol; 2004 Jun; 11(6):630-6. PubMed ID: 15172365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MR enteroclysis using iron oxide particles (ferristene) as an endoluminal contrast agent: an open phase III trial.
    Boraschi P; Braccini G; Gigoni R; Cartei F; Perri G
    Magn Reson Imaging; 2004 Oct; 22(8):1085-95. PubMed ID: 15527995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of new manganese contrast agent on tissue intensities in human volunteers: comparison of 0.23, 0.6 and 1.5 T MRI, a part of a phase I trial.
    Chabanova E; Thomsen HS; Løgager V; Moller JM; Brage K; Fogh K; Bovin J; Elmig J
    MAGMA; 2004 Sep; 17(1):28-35. PubMed ID: 15258827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T1-Weighted Contrast-Enhanced Magnetic Resonance Imaging of the Small Bowel: Comparison Between 1.5 and 7 T.
    Hahnemann ML; Kraff O; Orzada S; Umutlu L; Kinner S; Ladd ME; Quick HH; Lauenstein TC
    Invest Radiol; 2015 Aug; 50(8):539-47. PubMed ID: 25945458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionictetra-acetate (BOPTA)--preliminary results of phase II clinical application.
    Caudana R; Morana G; Pirovano GP; Nicoli N; Portuese A; Spinazzi A; Di Rito R; Pistolesi GF
    Radiology; 1996 May; 199(2):513-20. PubMed ID: 8668804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging liver metastases with a new oral manganese-based contrast agent.
    Chabanova E; Logager V; Moller JM; Dekker H; Barentsz J; Thomsen HS
    Acad Radiol; 2006 Jul; 13(7):827-32. PubMed ID: 16777556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study.
    Bluemke DA; Sahani D; Amendola M; Balzer T; Breuer J; Brown JJ; Casalino DD; Davis PL; Francis IR; Krinsky G; Lee FT; Lu D; Paulson EK; Schwartz LH; Siegelman ES; Small WC; Weber TM; Welber A; Shamsi K
    Radiology; 2005 Oct; 237(1):89-98. PubMed ID: 16126918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.